[1. Kumar A, Cannon CP. Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc 2009; 84(10): 917–38.10.4065/84.10.917]Search in Google Scholar
[2. Boden H, van der Hoeven BL, Karalis I, Schalij MJ, Jukema JW. Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. J Intern Med 2012; 271(6): 521–36.10.1111/j.1365-2796.2012.02533.x22340431]Search in Google Scholar
[3. Patel NK, Elmariah S. Acute Coronary Syndromes. In: Lau JF, Barnes GD, Streiff MB, editors. Anticoagulation Therapy. Cham: Springer International Publishing; 2018. p. 197–216.10.1007/978-3-319-73709-6_10]Search in Google Scholar
[4. Dhoble A, Anderson HV. Strategies in Acute Coronary Syndrome. In: Lanzer P, editor. Textbook of Catheter-Based Cardiovascular Interventions. Cham: Springer International Publishing; 2018. p. 921–38.10.1007/978-3-319-55994-0_55]Search in Google Scholar
[5. Bassand JP. Drug interactions in the setting of acute coronary syndromes and dual anti-platelet therapy. Eur Heart J Suppl 2006; 8(suppl G): G35–7.10.1093/eurheartj/sul053]Search in Google Scholar
[6. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37(3): 267–315.10.1093/eurheartj/ehv32026320110]Search in Google Scholar
[7. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018; 39: 119–77.10.1093/eurheartj/ehx39328886621]Search in Google Scholar
[8. Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, et al. Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf 2015; 38(2): 197–206.10.1007/s40264-014-0262-8462432225556085]Search in Google Scholar
[9. Baxter K. (2010). Stockley’s Drug Interactions (9th ed.). London: Pharmaceutical Press.]Search in Google Scholar
[10. de Lima TAM, de Godoy MF. Drug-drug interactions in prescriptions for hospitalized elderly with Acute Coronary Syndrome. Rev Eletrônica Enferm 2017; 19: a24.]Search in Google Scholar
[11. Pejčić AV, Janković SM, Davidović G. Drug-drug interactions in patients with acute coronary syndrome across phases of treatment. Intern Emerg Med 2019; 14(3): 411–22.10.1007/s11739-018-1994-830483990]Search in Google Scholar
[12. Dunn SP, Holmes DR, Moliterno DJ. Drug-drug interactions in cardiovascular catheterizations and interventions. JACC Cardiovasc Interv 2012; 5(12): 1195–208.10.1016/j.jcin.2012.10.00523257367]Search in Google Scholar
[13. Snyder BD, Polasek TM, Doogue MP. Drug interactions: principles and practice. Aust Prescr 2012; 35: 85–8.10.18773/austprescr.2012.037]Search in Google Scholar
[14. Cecchi E. Drug-drug interaction knowledge to save the patient from iatrogenic disease and to improve the diagnostic process. Intern Emerg Med 2019; 14(3): 345–7.10.1007/s11739-018-02016-w30610439]Search in Google Scholar
[15. Zeymer U, Mark B, Montalescot G, Thiele H, Zahn R. Influence of morphine on the effect of clopidogrel and prasugrel in patients with ST elevation myocardial infarction. Results of the ETAMI trial. Eur Heart J 2015; 36(Abstract Supplement): 227–8.]Search in Google Scholar
[16. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2015; 8(1): e001593.10.1161/CIRCINTERVENTIONS.114.00159325552565]Search in Google Scholar
[17. Bellandi B, Zocchi C, Xanthopoulou I, Scudiero F, Valenti R, Migliorini A, et al. Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. Int J Cardiol 2016; 221: 567–71.10.1016/j.ijcard.2016.06.20427420579]Search in Google Scholar
[18. Thomas MR, Morton AC, Hossain R, Chen B, Luo L, Shahari NN, et al. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost 2016; 116(1): 96–102.10.1160/TH16-02-010227099137]Search in Google Scholar
[19. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37(3): 245–52.10.1093/eurheartj/ehv547471235126491112]Search in Google Scholar
[20. Franchi F, Rollini F, Cho JR, Bhatti M, DeGroat C, Ferrante E, et al. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. JACC Cardiovasc Interv 2015; 8(11): 1457–67.10.1016/j.jcin.2015.02.03026404199]Search in Google Scholar
[21. Silvain J, Storey RF, Cayla G, Esteve J-B, Dillinger J-G, Rousseau H, et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost 2016; 116(2): 369–78.10.1160/TH15-12-0944]Search in Google Scholar
[22. Lapostolle F, van’t Hof AW, Hamm CW, Stibbe O, Ecollan P, Collet J-P, et al. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. Am J Cardiovasc Drugs 2019; 19(2): 173–83.10.1007/s40256-018-0305-030353444]Search in Google Scholar
[23. Farag M, Spinthakis N, Srinivasan M, Sullivan K, Well-sted D, Gorog DA. Morphine Analgesia Pre-PPCI Is Associated with Prothrombotic State, Reduced Spontaneous Reperfusion and Greater Infarct Size. Thromb Hae-most 2018; 118(3): 601–12.10.1055/s-0038-162989629444530]Search in Google Scholar
[24. Bhurke SM, Martin BC, Li C, Franks AM, Bursac Z, Said Q. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy. 2012; 32(9): 809–18.10.1002/j.1875-9114.2012.01112.x353196222744772]Search in Google Scholar
[25. Ortolani P, Marino M, Marzocchi A, De Palma R, Branzi A. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study. J Cardiovasc Med (Hagerstown) 2012; 13(12): 783–9.10.2459/JCM.0b013e3283416b6b21252697]Search in Google Scholar
[26. Valkhoff VE, ’t Jong GW, Van Soest EM, Kuipers EJ, Sturkenboom MC. Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther 2011; 33(1): 77–88.10.1111/j.1365-2036.2010.04485.x21083580]Search in Google Scholar
[27. Tsai YW, Wen YW, Huang WF, Chen PF, Kuo KN, Hsiao FY. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol 2011; 46(1): 39–45.10.1007/s00535-010-0299-020811753]Search in Google Scholar
[28. Sheng-Wen Wang S, Tsai SS, Hsu PC, Yang CY, Wu DC. Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction. Am J Gastroenterol 2009; 104(12): 3116–7.10.1038/ajg.2009.52519956146]Search in Google Scholar
[29. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120(23): 2322–9.10.1161/CIRCULATIONAHA.109.873497281878919933932]Search in Google Scholar
[30. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301(9): 937–44.10.1001/jama.2009.26119258584]Search in Google Scholar
[31. Depta JP, Lenzini PA, Lanfear DE, Wang TY, Spertus JA, Bach RG, et al. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J 2015; 15(1): 20–5.10.1038/tpj.2014.28428745925001880]Search in Google Scholar
[32. Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of Acute Myocardial Infarction in Patients Discharged on Clopidogrel and a Proton Pump Inhibitor After Stent Placement for Acute Myocardial Infarction. Clin Cardiol 2010; 33(3): 168–71.10.1002/clc.20721665345620235209]Search in Google Scholar
[33. Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation 2012; 125(8): 978–86.10.1161/CIRCULATIONAHA.111.03291222261200]Search in Google Scholar
[34. Jackson LR, Peterson ED, McCoy LA, Ju C, Zettler M, Baker BA, et al. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. J Am Heart Assoc 2016;5(10).10.1161/JAHA.116.003824512148527792656]Search in Google Scholar
[35. Zou JJ, Chen SL, Tan J, Lin L, Zhao YY, Xu HM, et al. Increased Risk for Developing Major Adverse Cardiovascular Events in Stented Chinese Patients Treated with Dual Antiplatelet Therapy after Concomitant Use of the Proton Pump Inhibitor. PLOS ONE 2014; 9(1): e84985.10.1371/journal.pone.0084985388564724416326]Search in Google Scholar
[36. Parri MS, Gianetti J, Dushpanova A, Della Pina F, Saracini C, Marcucci R, et al. Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial. Int J Cardiol 2013; 167(5): 2177–81.10.1016/j.ijcard.2012.05.08022727972]Search in Google Scholar
[37. Fernando H, Bassler N, Habersberger J, Sheffield LJ, Sharma R, Dart AM, et al. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost 2011; 9(8): 1582–9.10.1111/j.1538-7836.2011.04414.x21696537]Search in Google Scholar
[38. Chyrchel B, Surdacki A, Chyrchel M, Dudek D, Dubiel JS. Separate dosing of clopidogrel and omeprazole may improve platelet inhibition on dual antiplatelet therapy. Int J Cardiol 2011; 149(1): 124–5.10.1016/j.ijcard.2011.01.09121345502]Search in Google Scholar
[39. Fontes-Carvalho R, Albuquerque A, Araújo C, Pimentel-Nunes P, Ribeiro VG. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocar-dial infarction evaluating the clopidogrel–PPIs drug interaction. Eur J Gastroenterol Hepatol 2011; 23(5): 396–404.10.1097/MEG.0b013e328346011021464720]Search in Google Scholar
[40. Ren Y, Zhao M, Chen Y, Chen L, Liu H, Wang Y, et al. Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. Chin Med J (Engl) 2011; 124(6): 856–61.]Search in Google Scholar
[41. Tsukahara K, Kimura K, Morita S, Ebina T, Kosuge M, Hibi K, et al. Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. J Cardiol 2011; 57(3): 275–82.10.1016/j.jjcc.2011.01.00321371863]Search in Google Scholar
[42. Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54(13): 1149–53.10.1016/j.jacc.2009.05.05019761935]Search in Google Scholar
[43. Zhang J, Wang D, Du J, Qu G, Du J, Deng S, et al. Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial. Medicine (Baltimore) 2015; 94(50): e2262.10.1097/MD.0000000000002262505892126683949]Search in Google Scholar
[44. Liu LP, Wang Y, Si R, Yuan M, Cheng K, Guo WY. Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case–control study. Expert Opin Pharmacother 2016; 17(1): 7–16.10.1517/14656566.2016.111014526549402]Search in Google Scholar
[45. Lu F, Tong Z, Mao Y, Wu D, Xu J. [Impact of proton pump inhibitor omeprazole on the antiplatelet effect of clopidogrel in individuals with various CYP2C19*2 genotypes]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012; 29(4): 478–81.]Search in Google Scholar
[46. Yano H, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, et al. Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. Circ J 2012; 76(11): 2673–80.10.1253/circj.CJ-12-051122864179]Search in Google Scholar
[47. Bolek T, Samoš M, Šimonová R, Kovář F, Fedor M, Galajda P, et al. Does Pantoprazole Affect the On-Treatment Platelet Reactivity in Patients With Acute STEMI Treated With ADP Receptor Blockers?-A Pilot Prospective Study. Am J Ther 2017; 24(2): e162–6.10.1097/MJT.000000000000045427415979]Search in Google Scholar
[48. Lin CF, Shen LJ, Wu FL, Bai CH, Gau CS. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. Br J Clin Pharmacol 2012; 74(5): 824–34.10.1111/j.1365-2125.2012.04250.x349514722364155]Search in Google Scholar
[49. Macaione F, Montaina C, Evola S, Novo G, Novo S. Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation. ISRN Cardiol 2012; 2012: 692761.10.5402/2012/692761339193622792485]Search in Google Scholar
[50. Chitose T, Hokimoto S, Oshima S, Nakao K, Fujimoto K, Miyao Y, et al. Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor. Circ J 2012; 76(1): 71–8.10.1253/circj.CJ-11-069922130313]Search in Google Scholar
[51. Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW. Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. Pharmacoepidemiol Drug Saf 2011; 20(10): 1043–9.10.1002/pds.220221823195]Search in Google Scholar
[52. Douglas IJ, Evans SJW, Hingorani AD, Grosso AM, Timmis A, Hemingway H, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ 2012; 345: e4388.10.1136/bmj.e4388339295622782731]Search in Google Scholar
[53. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011; 123(5): 474–82.10.1161/CIRCULATIONAHA.110.96564021262992]Search in Google Scholar
[54. Gaspar A, Ribeiro S, Nabais S, Rocha S, Azevedo P, Pereira MA, et al. Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome. Rev Port Cardiol 2010; 29(10): 1511–20.]Search in Google Scholar
[55. Amariles P, Holguín H, Angulo NY, Betancourth PM, Ceballos M. [Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study]. Aten Primaria 2014; 46(8): 426–32.10.1016/j.aprim.2013.11.007698560424581893]Search in Google Scholar
[56. Gao QP, Sun Y, Sun YX, Wang LF, Fu L. Early use of omeprazole benefits patients with acute myocardial infarction. J Thromb Thrombolysis 2009; 28(3): 282–7.10.1007/s11239-008-0282-218830566]Search in Google Scholar
[57. Wu H, Jing Q, Wang J, Guo X. Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. J Crit Care 2011; 26(4): 434.e1–6.10.1016/j.jcrc.2010.12.00721273036]Search in Google Scholar
[58. Aradi D, Kuliczkowski W, Atar D, Serebruany VL. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb Hae-most 2012; 107(2): 338–45.10.1160/TH11-09-062222186910]Search in Google Scholar
[59. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011; 342: d2690.10.1136/bmj.d2690309252021562004]Search in Google Scholar
[60. Kasprzak M, Koziński M, Bielis L, Boinska J, Plazuk W, Marciniak A, et al. Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J 2009; 16(6): 535–44.]Search in Google Scholar
[61. Hudson M, Baron M, Rahme E, Pilote L. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. J Rheumatol 2005; 32(8): 1589–93.]Search in Google Scholar
[62. Schjerning Olsen AM, Gislason GH, McGettigan P, Fosbøl E, Sørensen R, Hansen ML, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA 2015; 313(8): 805–14.10.1001/jama.2015.080925710657]Search in Google Scholar
[63. Curtis JP, Wang Y, Portnay EL, Masoudi FA, Havranek EP, Krumholz HM. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 2003; 327(7427): 1322–3.10.1136/bmj.327.7427.132228631914656840]Search in Google Scholar
[64. Lindvall G, Sartipy U, Bjessmo S, Svenarud P, Lindvall B, van der Linden J. Aprotinin reduces the antiplatelet effect of clopidogrel. Interact Cardiovasc Thorac Surg 2009; 9(2): 178–81.10.1510/icvts.2009.20634219477870]Search in Google Scholar
[65. Wang CY, Lin ZF, Lee CM, Tsai YW, Huang TY, Shen LJ, et al. Concomitant use of calcium channel blockers with dual antiplatelet therapy and re-hospitalization for acute coronary syndrome. Pharmacoepidemiol Drug Saf 2017; 26(3): 229–38.10.1002/pds.414728067454]Search in Google Scholar
[66. Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, et al. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv 2013; 6(12): 1275–81.10.1016/j.jcin.2013.06.01424239201]Search in Google Scholar
[67. Olesen JB, Gislason GH, Charlot MG, Fosbøl EL, Andersson C, Weeke P, et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J Am Coll Cardiol 2011; 57(4): 409–17.10.1016/j.jacc.2010.08.64021251580]Search in Google Scholar
[68. Thotakura S, Singh A, Khera K, Chauhan S, Devasia T. Atorvastatin-induced hepatotoxicity, increased by clopidogrel stress on CYP450 Enzyme: Understanding the mechanism through a case. J Appl Pharm Sci 2018; 8(4): 168–170.10.7324/JAPS.2018.8424]Search in Google Scholar
[69. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin Does Not Affect the Antiplatelet Potency of Clopidogrel When It Is Administered Concomitantly for 5 Weeks in Patients With Acute Coronary Syndromes. Circulation. 2004; 109(11): 1335–8.10.1161/01.CIR.0000124581.18191.1515023882]Search in Google Scholar
[70. Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP, TIMI 22 Investigators. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients-a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J 2008; 155(5): 954–8.10.1016/j.ahj.2007.12.00918440347]Search in Google Scholar
[71. Lim MJ, Spencer FA, Gore JM, Dabbous OH, Agnelli G, Kline-Rogers EM, et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. Eur Heart J 2005; 26(11): 1063–9.10.1093/eurheartj/ehi139]Search in Google Scholar
[72. Han Y, Li C, Li Y, Kang J, Yan C. [The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting]. Zhonghua Xin Xue Guan Bing Za Zhi 2007; 35(9): 788–92.]Search in Google Scholar
[73. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart Br Card Soc 2005; 91(1): 23–6.10.1136/hrt.2004.035014]Search in Google Scholar
[74. Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92(3): 285–8.10.1016/S0002-9149(03)00626-X]Search in Google Scholar
[75. Pourdjabbar A, Hibbert B, Chong AY, Abunassar J, Malhotra N, Whitten TA, et al. A pharmacodynamic analysis for the co-administration of inducers of CYP3A with ticagrelor: A cautionary tale in managing patients with acute coronary syndromes. Int J Cardiol 2016; 214: 423–5.10.1016/j.ijcard.2016.03.153]Search in Google Scholar
[76. Romeo F, Rosano GM, Martuscelli E, De Luca F, Bianco C, Colistra C, et al. Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction. Am Heart J 1995; 130(4): 692–7.10.1016/0002-8703(95)90065-9]Search in Google Scholar
[77. Nicolini FA, Ferrini D, Ottani F, Galvani M, Ronchi A, Behrens PH, et al. Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction. Am J Cardiol 1994; 74(7): 662–6.10.1016/0002-9149(94)90306-9]Search in Google Scholar
[78. Becker RC, Corrao JM, Bovill EG, Gore JM, Baker SP, Miller ML, et al. Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality. Am Heart J 1990; 119(6): 1254–61.10.1016/S0002-8703(05)80172-3]Search in Google Scholar
[79. Habbab MA, Haft JI. Heparin resistance induced by intravenous nitroglycerin. A word of caution when both drugs are used concomitantly. Arch Intern Med 1987; 147(5): 857–60.10.1001/archinte.1987.00370050053009]Search in Google Scholar
[80. Gonzalez ER, Jones HD, Graham S, Elswick RK. Assessment of the drug interaction between intravenous nitroglycerin and heparin. Ann Pharmacother 1992; 26(12): 1512–4.10.1177/1060028092026012031482804]Search in Google Scholar
[81. Nottestad SY, Mascette AM. Nitroglycerin-induced heparin resistance: absence of interaction at clinically relevant doses. Mil Med 1994; 159(8): 569–71.10.1093/milmed/159.8.569]Search in Google Scholar
[82. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494–502.10.1056/NEJMoa01074611519503]Search in Google Scholar
[83. Gille J, Bernotat J, Böhm S, Behrens P, Löhr JF. Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. Z Rheumatol 2003; 62(1): 80–1.10.1007/s00393-003-0420-312624808]Search in Google Scholar
[84. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110(10): 1202–8.10.1161/01.CIR.0000140675.85342.1B15313956]Search in Google Scholar
[85. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372(19): 1791–800.10.1056/NEJMoa150085725773268]Search in Google Scholar
[86. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357(20): 2001–15.10.1056/NEJMoa070648217982182]Search in Google Scholar
[87. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361(11): 1045–57.10.1056/NEJMoa090432719717846]Search in Google Scholar
[88. Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, et al. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Am J Cardiol 2015; 115(10): 1325–32.10.1016/j.amjcard.2015.02.04325776457]Search in Google Scholar
[89. Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, et al. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50. Circulation 2015; 132(20): 1871–9.10.1161/CIRCULATIONAHA.114.01504226338971]Search in Google Scholar
[90. Tricoci P, Lokhnygina Y, Huang Z, Van de Werf F, Cornel JH, Chen E, et al. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Am Heart J 2014; 168(6): 869–77.e1.10.1016/j.ahj.2014.09.00225458650]Search in Google Scholar
[91. Hess CN, James S, Lopes RD, Wojdyla DM, Neely ML, Liaw D, et al. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. J Am Coll Cardiol 2015; 66(7): 777–87.10.1016/j.jacc.2015.06.02726271059]Search in Google Scholar
[92. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. J Am Coll Cardiol 2001; 37(2): 475–84.10.1016/S0735-1097(00)01118-9]Search in Google Scholar
[93. Sámóczi M, Farkas A, Sipos E, Tarján J. [Adverse effects of combined use of acenocoumarol and acetylsalicylic acid after myocardial infarct and unstable angina]. Orv Hetil 1995; 136(4): 177–9.]Search in Google Scholar
[94. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med. 2005; 165(7): 784–9.10.1001/archinte.165.7.784]Search in Google Scholar
[95. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374(9706): 1967–74.10.1016/S0140-6736(09)61751-7]Search in Google Scholar
[96. Stiles MK, Dabbous OH, Fox KAA, GRACE investigators. Bleeding events with antithrombotic therapy in patients with unstable angina or non-ST-segment elevation myocardial infarction; insights from a large clinical practice registry (GRACE). Heart Lung Circ 2008; 17(1): 5–8.10.1016/j.hlc.2007.02.09617419100]Search in Google Scholar
[97. Kim JH, Jeong MH, Rhew JY, Lim JH, Yun KH, Kim KH, et al. Long-Term Clinical Outcomes of Platelet Glycoprotein IIb/IIIa Inhibitor Combined With Low Molecular Weight Heparin in Patients With Acute Coronary Syndrome. Circ J 2005; 69(2): 159–64.10.1253/circj.69.15915671606]Search in Google Scholar
[98. Savonitto S, Armstrong PW, Lincoff AM, Jia G, Sila CA, Booth J, et al. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J 2003; 24(20): 1807–14.10.1016/j.ehj.2003.07.00414563339]Search in Google Scholar
[99. Sinnaeve PR, Huang Y, Bogaerts K, Vahanian A, Adgey J, Armstrong PW, et al. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: Findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS. Am Heart J 2006; 152(4): 684.e1–9.10.1016/j.ahj.2006.07.00516996833]Search in Google Scholar
[100. Amissah-Arthur KN, Groppe M, Scotcher S. Orbital subperiosteal hematoma after thrombolysis and anticoagulation for acute myocardial infarction. J Neuroophthalmol 2009; 29(3): 250–1.10.1097/WNO.0b013e3181b56a3d19726950]Search in Google Scholar
[101. Ganeva M, Gancheva T, Baldaranov I, Troeva J, Hristakieva E. Screening for adverse drug interactions in dermatology patients. Trakia J Sci 2010; 8(2): 266–71.]Search in Google Scholar
[102. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183(16): 1835–43.10.1503/cmaj.100912321645521948719]Search in Google Scholar
[103. Ing Lorenzini K, Daali Y, Fontana P, Desmeules J, Samer C. Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect. Front Pharmacol 2016; 7: 494.10.3389/fphar.2016.00494516525128066243]Search in Google Scholar
[104. Tseng AL, Luetkehoelter J, Walmsley SL. Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal. AIDS 2017; 31(1): 175–6.10.1097/QAD.000000000000127527898595]Search in Google Scholar
[105. van Sloten TT, de Klaver PAG, van den Wall Bake AWL. Co-administration of cyclosporine and ticagrelor may lead to a higher exposure to cyclosporine: a case report of a 49-year-old man. Br J Clin Pharmacol 2018; 84(1): 208–10.10.1111/bcp.13433573685028891590]Search in Google Scholar
[106. Zhang C, Shen L, Cui M, Liu X, Gu Z. Ticagrelor-induced life-threatening bleeding via the cyclosporine-mediated drug interaction: A case report. Medicine (Baltimore) 2017; 96(37): e8065.10.1097/MD.0000000000008065560467328906404]Search in Google Scholar
[107. Kristensen KE, Zhu HJ, Wang X, Gislason GH, Torp-Pedersen C, Rasmussen HB, et al. Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study. Clin Pharmacol Ther 2014; 96(6): 713–22.10.1038/clpt.2014.18325222620]Search in Google Scholar
[108. Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report. Am J Case Rep 2017; 18: 1238–41.10.12659/AJCR.905974570826129167415]Search in Google Scholar
[109. Kido K, Wheeler MB, Seratnahaei A, Bailey A, Bain JA. Rhabdomyolysis precipitated by possible interaction of ticagrelor with high-dose atorvastatin. J Am Pharm Assoc 2015; 55(3): 320–3.10.1331/JAPhA.2015.1415126003161]Search in Google Scholar
[110. Banakh I, Haji K, Kung R, Gupta S, Tiruvoipati R. Severe Rhabdomyolysis due to Presumed Drug Interactions between Atorvastatin with Amlodipine and Ticagrelor. Case Rep Crit Care 2017; 2017: 3801819.10.1155/2017/3801819546311228630772]Search in Google Scholar
[111. van Vuren AJ, de Jong B, Bootsma HPR, Van der Veen MJ, Feith GW. Ticagrelor-induced renal failure leading to statin-induced rhabdomyolysis. Neth J Med. 2015; 73(3): 136–8.]Search in Google Scholar
[112. Cenjor Martín R, Gutiérrez-Madrid E, Martín-Sánchez FJ, Cuervo Pinto R. [Iatrogenic rhabdomyolysis in a patient with ischemic heart disease]. Med Clin (Barc). 2016; 146(10): e57–8.10.1016/j.medcle.2016.06.045]Search in Google Scholar
[113. Jozic T, Terzic B, Mitrovic P, Kostic J, Milanov M, Stojanovic M, et al. Combined statin-fibrate therapy-induced rhabdomyolysis: Case report. Hospital Pharmacology - International Multidisciplinary Journal 2014; 1(1): 22–6.10.5937/hpimj1401022J]Search in Google Scholar
[114. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med 1990; 112(3): 228–30.10.7326/0003-4819-112-3-2282297197]Search in Google Scholar
[115. Peces R, Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 2001; 89(1): 117–8.10.1159/00004605611528245]Search in Google Scholar
[116. Liu Y, Cheng Z, Ding L, Fang F, Cheng KA, Fang Q, et al. Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Int J Clin Pharmacol Ther 2010; 48(12): 798–802.10.5414/CPP48798]Search in Google Scholar
[117. Tada T, Nakata J, Sugawara H, Nishizawa K, Sunaga D, Sato K, et al. [Case report; Selective serotonin reuptake inhibitor induced QT prolongation and ventricular fibrillation in acute myocardial infarction]. Nihon Naika Gakkai Zasshi 2014; 103(3): 738–40.10.2169/naika.103.738]Search in Google Scholar
[118. Vural M. [Role of the drug interaction between carve-dilol and dobutamine in inducing of severe hypotension in a case with acute coronary syndrome]. Anadolu Kardiyol Derg 2007; 7(2): 229.]Search in Google Scholar
[119. Fareed FN, Chan G, Hoffman RS. Death temporally related to the use of a Beta adrenergic receptor antagonist in cocaine associated myocardial infarction. J Med Toxicol 2007; 3(4): 169–72.10.1007/BF03160934]Search in Google Scholar
[120. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 2008; 64(3): 275–82.10.1007/s00228-007-0404-3]Search in Google Scholar
[121. Bebawi E, Jouni SS, Tessier A-A, Frenette AJ, Brindamour D, Doré M. A metoprolol-terbinafine combination induced bradycardia. Eur J Drug Metab Pharmacokinet 2015; 40(3): 295–9.10.1007/s13318-014-0205-x]Search in Google Scholar
[122. Alsindi A, Murphy C, Martin D. Amiodarone-induced torsades de pointes in a patient with HIV on combination antiretroviral therapy. Grand Rounds 2010; 10: 28–33.]Search in Google Scholar
[123. Renet S, Chaumais MC, Antonini T, Zhao A, Thomas L, Savoure A, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015; 149(6): 1378–1380.e1.10.1053/j.gastro.2015.07.051]Search in Google Scholar
[124. Kessler KM, Interian A, Cox M, Topaz O, De Marchena EJ, Myerburg RJ. Proarrhythmia related to a kinetic and dynamic interaction of mexiletine and theophylline. Am Heart J 1989; 117(4): 964–6.10.1016/0002-8703(89)90637-6]Search in Google Scholar
[125. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Study II (CONSENSUS II). Am J Cardiol 1997; 79(2): 115–9.10.1016/S0002-9149(96)00696-0]Search in Google Scholar
[126. Latini R, Santoro E, Masson S, Tavazzi L, Maggioni AP, Franzosi MG, et al. Aspirin does not interact with ACE inhibitors when both are given early after acute myocar-dial infarction: results of the GISSI-3 Trial. Heart Dis 2000; 2(3): 185–90.]Search in Google Scholar
[127. Oosterga M, Anthonio RL, de Kam PJ, Kingma JH, Crijns HJ, van Gilst WH. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol 1998; 81(10): 1178–81.10.1016/S0002-9149(98)00153-2]Search in Google Scholar
[128. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327(10): 669–77.10.1056/NEJM1992090332710011386652]Search in Google Scholar
[129. Krumholz HM, Chen YT, Wang Y, Radford MJ. Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocar-dial infarction. Arch Intern Med 2001; 161(4): 538–44.10.1001/archinte.161.4.53811252112]Search in Google Scholar
[130. Hanna ER, Clark JA. Serotonin syndrome after cardio-pulmonary bypass: a case demonstrating the interaction between methylene blue and selective serotonin reuptake inhibitors. Case Rep 2014; 2(9): 113–4.10.1213/XAA.0000000000000010]Search in Google Scholar
[131. Kelesidis T, Kelesidis I. Unexplained high fever in an elderly patient treated with clonidine, duloxetine, and atorvastatin. Clin Ther 2009; 31(12): 2894–9.10.1016/j.clinthera.2009.12.008805633220110028]Search in Google Scholar
[132. Siller-Matula JM, Trenk D, Krähenbühl S, Michelson AD, Delle-Karth G. Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost 2014; 12(1): 2–13.10.1111/jth.1244524406062]Search in Google Scholar
[133. Khan SU, Lone AN, Asad ZUA, Rahman H, Khan MS, Saleem MA, et al. Meta-analysis of efficacy and safety of proton pump inhibitors with dual antiplatelet therapy for coronary artery disease. Cardiovasc Revasc Med [In press] doi: 10.1016/j.carrev.2019.02.00210.1016/j.carrev.2019.02.002748946330773427]Search in Google Scholar
[134. Chen M, Wei JF, Xu YN, Liu XJ, Huang DJ. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. Cardiovasc Ther 2012; 30(5): e227-233.10.1111/j.1755-5922.2011.00289.x21884023]Search in Google Scholar
[135. Melloni C, Washam JB, Jones WS, Halim SA, Hasselblad V, Mayer SB, et al. Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. Circ Cardiovasc Qual Outcomes 2015; 8(1): 47–55.10.1161/CIRCOUTCOMES.114.001177614313825587094]Search in Google Scholar
[136. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018; 39: 213–60.10.1093/eurheartj/ehx41928886622]Search in Google Scholar
[137. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocar-dial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Survival Management of Patients Undergoing Noncardiac Surgery. Circulation 2016; 134(10): e123–55.10.1161/CIR.0000000000000404]Search in Google Scholar
[138. D’Ugo E, Rossi S, De Caterina R. Proton pump inhibitors and clopidogrel: an association to avoid? Intern Emerg Med 2014; 9(1): 11–22.10.1007/s11739-013-1000-4]Search in Google Scholar
[139. Food and Drug Administration U.S. Department of Health and Human Services. Concomitant use of ibuprofen and aspirin. J Pain Palliat Care Pharmacother 2007; 21(2): 73–4.10.1080/J354v21n02_14]Search in Google Scholar
[140. Ghadban R, Enezate T, Payne J, Allaham H, Halawa A, Fong HK, et al. The safety of morphine use in acute coronary syndrome: a meta-analysis. Heart Asia 2019; 11(1): e011142.10.1136/heartasia-2018-011142645432731031833]Search in Google Scholar
[141. Kubica J, Kubica A, Jilma B, Adamski P, Hobl EL, Navarese EP, et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol 2016; 215: 201–8.10.1016/j.ijcard.2016.04.07727128531]Search in Google Scholar
[142. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32(15): 1854–64.10.1093/eurheartj/ehr20421715717]Search in Google Scholar
[143. Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB, et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2016; 134(21): e468–95.10.1161/CIR.0000000000000456]Search in Google Scholar
[144. Danielak D, Karaźniewicz-Łada M, Główka F. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs 2018; 78: 1105–12.10.1007/s40265-018-0947-x]Search in Google Scholar
[145. Takkouche B, Etminan M, Caamaño F, Rochon PA. Interaction Between Aspirin and ACE Inhibitors. Drug Saf 2002; 25(5): 373–8.10.2165/00002018-200225050-00005]Search in Google Scholar
[146. Borghi C, Ambrosioni E, Novo S, Vinereanu D, Ambrosio G, SMILE-4 Working Party. Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dys-function after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin Cardiol 2012; 35(7): 416–23.10.1002/clc.22017]Search in Google Scholar
[147. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368(9535): 581–8.10.1016/S0140-6736(06)69201-5]Search in Google Scholar